Free Trial

KBC Securities' Rating of Avidity Biosciences on 10/13/2014

On October 13, 2014, KBC Securities updated its outlook on Avidity Biosciences (NASDAQ:RNA) with the action "Boost Price Target", setting a price target of $17.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.